BioLargo, Inc.

16 articles with BioLargo, Inc.

• BioLargo Revenue Continues Breaking Records as Water Technologies Ready for Commercialization

  11/16/2020

  BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, filed with the SEC its Quarterly Report on Form 10-Q for the period ended September 30, 2020 ( www.biolargo.com/sec-filings ). BioLargos Third Quarter Accomplishments Record revenue - generated record revenues in the third quarter, rebounding from early pandemic shutdowns

• BioLargo Awarded Contract for Engineering Services at Major Chemical Manufacturing Facility

  10/21/2020

  BioLargo, Inc, announced today that its subsidiary BioLargo Engineering, Science & Technologies (BLEST) has been awarded a contract to assist in the reconfiguration of the Regenerative Thermal Oxidizer (RTO) systems used at a large chemical manufacturing plant on the East Coast of the US, owned by a global chemical company,

• BioLargo Subsidiary Clyra Medical’s Clyraguard Product Shows Complete Inactivation of SARS-CoV-2 Virus in Galveston National Lab Study

  5/21/2020

  BioLargo, Inc. announced that Clyraguard, the product developed by its partially owned subsidiary Clyra Medical Technologies in response to the COVID-19 pandemic has been successfully shown to cause complete inactivation of the SARS-CoV-2 virus in laboratory testing.

• Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast to Discuss the Company’s Record-Breaking Quarterly Results and a Progress Report on its March to its First Industry-Wide Adoption

  8/16/2018

  Dennis Calvert, CEO of BioLargo, Inc. (OTCQB: BLGO) recently spoke with “Stock Day” host Everett Jolly about BioLargo’s progress since the previous show at the end of July.

• BioLargo, Inc.'s Medical Subsidiary Files 510(K) With FDA For Its Novel Wound Care Technology

  9/28/2017

• BioLargo, Inc. Secures Financing For Its Advanced Wound Care Products Targeting FDA Application, Approval And Commercialization Through Its Subsidiary Clyra Medical Technologies

  1/8/2016

• BioLargo, Inc. Issued Patent For Its Platform Of Liquid And Hydrogel Iodine Technologies

  11/13/2014

• BioLargo, Inc. Granted Additional Patent As It Lands Second Order From US Government

  11/18/2013

• BioLargo, Inc. Achieves Breakout Milestones in Advanced Wound Care on Track for FDA 510(k) Submission and Commercialization

  12/17/2012

• BioLargo, Inc. Adds Wound Management Expert and Former VP at Smith & Nephew Inc., Tanya Rhodes, to Its Team

  8/6/2012

• BioLargo, Inc. Forms Medical Products Subsidiary to Focus on Advanced Wound Care

  5/15/2012

• BioLargo, Inc. Granted Key Patents

  9/29/2011

• BioLargo, Inc. Adds Key Medical Industry Executive - Tim R. Johnson

  8/24/2011

• BioLargo, Inc. Adds Water Expert and Former Pepsi-Cola International VP-Technical Services -- Harry DeLonge to Its Team

  2/24/2011

• BioLargo, Inc. Enters into Marketing Agreement for Leading Iodine Disinfection Technology

  8/25/2008

• NuWay Medical, Inc. Changes Name to BioLargo, Inc.; Announces Reverse Stock Split, Recapitalization, and Conversion of Debt and Payables to Equity

  3/22/2007